Kratom & Opioid Withdrawal: What Does Research Show – and What Do Those Affected Report? - Kratoein

Kratom & Opioid Withdrawal: What the Research Shows – and What Self-Reports Cannot Prove

Opioid withdrawal is one of those subjects where a great deal is asserted online and very little is evidenced. This article sets out what has actually been studied about Mitragyna speciosa in this field, what rank each type of data source holds – and why the most important section of this text is the one pointing to the established sources of help.

Opioid dependence is one of the most consequential substance use disorders of our time. In the USA, more than 130 people die every day from opioid overdoses; in Europe the figures are rising more slowly, but measurably. Against this backdrop, a great many stories circulate about what supposedly helps. Stories are not evidence, and on this subject that distinction is not an academic nicety – it decides lives.

The article therefore keeps three levels strictly apart: the pharmacology, the state of the data together with its evidentiary weight, and the routes that are genuinely available. What it expressly does not do is suggest a use.

Why opioid withdrawal is pharmacologically so hard

To understand why opioid withdrawal is so difficult to get through, you have to look at the receptor level. Opioids bind at the μ-opioid receptor, a G protein-coupled receptor which, via the inhibitory Gi protein, suppresses adenylyl cyclase and thereby lowers cellular cAMP levels. The body is not a passive vessel: it counter-regulates. Under sustained receptor occupancy, adenylyl cyclase is upregulated so that cAMP returns to a normal level despite the continuing suppression.

That counter-regulation is precisely the problem. When the opioid falls away, the suppression is gone – the upregulated adenylyl cyclase carries on unchecked and cAMP overshoots well beyond normal. In the locus coeruleus, the main noradrenergic nucleus of the brainstem, this produces a massive release of noradrenaline. Physical withdrawal is, at its core, a noradrenergic storm: sweating, gooseflesh, watering eyes, running nose, dilated pupils, rising blood pressure and heart rate, diarrhoea, vomiting, muscle and limb pain, restlessness, sleeplessness.

The timing follows the half-life of the substance involved. With short-acting opioids such as heroin or oxycodone, symptoms typically begin after 8 to 12 hours, peak at 36 to 72 hours and physically subside over roughly five to seven days. With methadone and its long half-life, withdrawal starts later and drags on for two to three weeks. On top of this comes what is termed protracted withdrawal: disturbed sleep, low drive, irritability and strong craving can persist for weeks to months, long after the physical signs have gone.

The most dangerous aspect of withdrawal is not the suffering but what follows it. Withdrawal strips away tolerance. Anyone who relapses at their previously habitual amount after a period of abstinence encounters a dose the body can no longer compensate for. Respiratory depression is the mechanism by which people die in opioid overdose. This is why the period immediately after withdrawal – after detoxification, after a hospital stay, after release from prison – is epidemiologically the phase carrying the highest mortality risk across the whole course of the illness. Any consideration of this subject that omits this point is incomplete.

The pharmacological basis – and where it ends

The alkaloids of Mitragyna speciosa – above all mitragynine and the metabolite 7-hydroxymitragynine – bind at the same receptor targeted by prescription opioids and heroin. That explains both why the subject is discussed pharmacologically at all and why the concerns are legitimate: the same receptor also means the same receptor adaptation, and therefore the same basis for tolerance and withdrawal.

Mitragynine is described in the literature as a partial agonist at the μ receptor: it activates the receptor, but with lower intrinsic activity than classical full agonists. A G protein-preferring signalling profile with comparatively weak β-arrestin-2 recruitment is also discussed. That observation comes predominantly from cell models; what significance it holds in humans is unresolved and is debated controversially in the specialist literature.

The comparison that regularly arises here is buprenorphine: likewise a partial μ agonist, likewise with a profile that differs from full agonists. The comparison describes a similarity in mechanism – nothing more. What separates buprenorphine from a plant extract is exactly the set of properties by which medicinal quality is measured:

Defined content: A medicinal product contains a declared, analytically verified quantity of an active substance. Plant material varies considerably in alkaloid content according to origin, harvest time, drying and processing.
Known pharmacokinetics: For authorised medicines, absorption, distribution, metabolism and excretion have been characterised in human studies. Mitragynine is metabolised via CYP3A4 and CYP2D6, among others – enzymes with pronounced genetic variants and numerous interactions.
Documented safety in combination: For substitution medicines, interactions and risk constellations have been systematically investigated and recorded in the product information.
Medical supervision: In a therapy, the pharmacological mechanism is only one component; dose finding, monitoring and psychosocial support are inseparable parts of it.

A mechanistic similarity is therefore a starting point for research – and not a statement about benefit.

The gold standard: medically supervised substitution therapy

Opioid substitution treatment is the best-studied route out of opioid dependence. In Germany it is governed by the Narcotic Drugs Prescription Ordinance (BtMVV) and is covered by the statutory health insurers. The substances chiefly used are methadone, levomethadone and buprenorphine, the last frequently combined with naloxone to make misuse by injection unattractive.

The decisive point is not comfort but the data on mortality. Cohort studies and meta-analyses agree that mortality during ongoing substitution treatment is markedly lower than during periods without treatment – and that the time immediately after a treatment is broken off is particularly dangerous. This is the most robust finding the field has to offer. It comes not from individual cases but from large datasets over long periods.

The treatment also works on several levels at once: it stabilises receptor status and thereby ends the swing between intoxication and withdrawal, it reduces the risk of infection from injecting, and it decouples daily life from procurement, which is what first creates the conditions for work, housing and social ties. In addition, naloxone is available as an emergency medicine that reverses an opioid overdose within minutes; take-home naloxone programmes are aimed specifically at those affected and the people around them.

Why buprenorphine occupies a special pharmacological position – and why this particular comparison is drawn so often and so imprecisely – is set out in detail in: What is buprenorphine? And why the comparison matters.

What has actually been studied about mitragynine in this field

The question is not whether publications exist – they do. The question is what rank they hold in the hierarchy of evidence. That hierarchy is not academic pedantry: it describes how well a data source can separate cause from effect.

Data source	What it can show	What it cannot show
Forum posts, personal accounts	That a topic exists and how it is talked about	Nothing about cause and effect; no data collection, no controls, strong self-selection
Case reports in specialist journals	That a course of events was observed this way; a prompt for hypotheses	No frequency, no comparison, no exclusion of other explanations
Surveys and self-report studies	How widespread patterns of use and motives are within the group surveyed	No objective measurement; response and recall bias; not generalisable to the wider population
Animal models (preclinical)	Mechanisms under controlled conditions	No statement about humans; species differences in metabolism and receptor biology
Randomised controlled trials	Cause and effect with a control group and blinding	Not published to date for this question in humans

Survey studies: In several US surveys of users – published in journals including Drug and Alcohol Dependence – a substantial share of respondents state that they use the plant in connection with opioid use; depending on the survey, proportions of over 40% are reported. That is a statement about motives and patterns of use within a self-selected group. It is expressly not a measurement of an effect: those who complete such surveys are predominantly content with what they are doing, while those who stopped appear systematically less often in such samples.

Case reports: The specialist literature contains documented individual courses in which patients describe a reduction of substitution medicines in connection with use of the plant. Case reports are a legitimate format in medicine – their purpose is to generate hypotheses, not to test them. They say nothing about how often a course looks like this and how often it looked different.

Preclinical findings: In rodent models, reduced withdrawal signs were observed following administration of mitragynine. This finding is preclinical and is not a statement about humans. Rodents differ markedly from humans in alkaloid metabolism; the quantities administered, the routes of administration and the measures used in animal experiments do not transfer.

What is missing: randomised controlled trials in humans, standardised preparations with declared content, comparator arms against established substitution treatment, and long-term data on mortality and retention in treatment. As long as these data are absent, there is no dependable statement to be made – in either direction.

What is described in publicly accessible forums

In online communities, forums and Reddit threads, people describe very varied courses of events: people who used heroin or oxycodone for years. People who did not tolerate methadone or buprenorphine programmes or could not access them. People in countries where substitution treatment is barely available.

These accounts are third-party, uncontrolled self-reports. They were not systematically collected, not verified and not compared. What is described there says nothing about what actually caused a given course of events, and it cannot be generalised. Four reasons make this source systematically unreliable:

Self-selection: Those who are satisfied write; those who stopped, who died, or who left the subject behind do not. That skews every picture in one direction.
No control group: A withdrawal course changes over time even without any additional substance. Without a comparison, there is no way to separate what was caused by what.
Unknown material: What was actually taken has not been analytically determined in any of these accounts. Content, composition and admixtures are unknown.
No verifiability: Identity, medical history, concomitant medication and subsequent course cannot be traced in any of these cases.

Equally, the same forums carry accounts in which a dependence of its own developed and getting off it is described as difficult. Both kinds of account carry the same – very limited – evidentiary weight. They are an indication that the subject deserves investigation, and no substitute for the investigation.

Documented potential for dependence

This is the part most often lost in the discussion, although it is among the best documented. For regular use of Mitragyna speciosa, the specialist literature describes development of tolerance, physical dependence and a withdrawal syndrome of its own. Pharmacologically this follows: occupying the same receptor over time triggers the same counter-regulation.

Described withdrawal signs include muscle and joint pain, disturbed sleep, restlessness, irritability, running nose, sweating, gastrointestinal complaints and pronounced craving. In the literature this withdrawal syndrome is predominantly described as milder than that of classical opioids – milder is not harmless, and that assessment again derives largely from self-reports.

Further documented risks come on top. The composition of non-standardised preparations varies considerably, particularly for concentrated products in which the 7-hydroxymitragynine content can be a multiple of that in plant material. Toxicological case series also regularly involve mixed constellations, that is, the simultaneous detection of other depressant substances. For combination with benzodiazepines, alcohol or other substances causing respiratory depression, an additive risk is pharmacologically to be expected and has been described in case reports.

Where the research stands – and why it stalls

The field is caught in a feedback loop that can be described soberly: a controlled clinical trial requires a standardised investigational preparation with declared content, a study protocol, an ethics committee, funding and a regulatory framework. For a substance whose legal status differs internationally and whose commercial material varies in content and composition, every one of these prerequisites is more laborious to meet than for a conventional drug candidate.

The result is a circle: no dependable data without trials, no trials without the framework conditions, which in turn are not created by reference to the absent data. Observing that this circle exists is a statement about the research system – and expressly not a statement about how such a trial would turn out. It is equally possible that it would demonstrate a benefit, show no difference, or reveal an unfavourable risk profile. That is precisely why trials are conducted.

Anyone forming a view today should therefore keep two sentences apart: “It is not established that it helps” and “It is established that it does not help”. The first is accurate. The second is not. And nothing follows from the first that would justify a use.

Where help is actually available

This is the most important section of this text. Anyone affected by opioid dependence, or supporting someone who is, will find established and free points of contact in Germany:

Addiction counselling services: Available nationwide, usually run by bodies such as Caritas, Diakonie, AWO, the Paritätischer Wohlfahrtsverband, or by local authorities. Counselling is free of charge, anonymous on request, and requires neither a diagnosis nor a referral.
Medically supervised substitution treatment: Through doctors qualified in addiction medicine, specialist practices and outpatient clinics. The treatment is covered by statutory health insurance and governed by the BtMVV.
The BZgA addiction and drugs helpline and the counselling services of the Federal Centre for Health Education, reachable around the clock, including for relatives.
Qualified inpatient withdrawal treatment: Physical withdrawal is monitored medically and supported with medication; the symptoms do not have to be endured unaided.
Take-home naloxone: In many regions, those affected and their relatives are given naloxone for emergency use along with training. In an overdose, that saves lives.
In an emergency: 112. If an opioid overdose is suspected – an unconscious person, shallow or interrupted breathing, pinpoint pupils – call the emergency services immediately.

None of these routes is interchangeable with a collector's item. These services exist, they are reachable, and they are the route for which dependable data exist.